Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia

Alexina Orsoni1, Elise F Villard, Eric Bruckert

  • 1INSERM UMRS939, Hôpital de la Pitié, Paris, France.

Journal of Lipid Research
|February 17, 2012
PubMed

Insights

LDL apheresis temporarily impairs reverse cholesterol transport (RCT) in familial hypercholesterolemia (FH) patients by reducing cholesterol efflux. However, high-density lipoprotein (HDL) particle function remains intact.

Area of Science:

  • Cardiovascular Medicine
  • Lipid Metabolism
  • Biochemistry

Background:

  • Familial hypercholesterolemia (FH) is characterized by low HDL cholesterol (HDL-C) and impaired reverse cholesterol transport (RCT).
  • Functional alterations in HDL particles reduce their RCT pathway efficacy in FH patients.

Purpose of the Study:

  • To evaluate the impact of LDL apheresis on the RCT pathway efficacy in FH patients.
  • To investigate how LDL apheresis affects cholesterol efflux and HDL particle function.

Main Methods:

  • Analysis of cholesteryl ester transfer protein (CETP)-mediated transfer and pre-β1-HDL levels.
  • Assessment of whole plasma and isolated HDL particle capacity for free cholesterol efflux from macrophages.
  • Evaluation of cholesterol ester delivery to hepatic cells.

Main Results:

  • LDL apheresis reduced CETP-mediated cholesteryl ester (CE) transfer and pre-β1-HDL levels.
  • Whole plasma's capacity for macrophage cholesterol efflux decreased, primarily due to reduced ABCA1-dependent pathways.
  • Isolated HDL particles retained their intrinsic capacity for cholesterol efflux and CE delivery to hepatic cells post-apheresis.

Conclusions:

  • LDL apheresis transiently reduces RCT efficacy by impacting cholesterol efflux mechanisms.
  • Despite temporary reductions in RCT, LDL apheresis does not alter the intrinsic functional capacity of HDL particles in FH patients.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...